clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Stomach Ulcer D013276 75 associated lipids
Hyperlipidemias D006949 73 associated lipids
Colitis D003092 69 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Pain D010146 64 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Psoriasis D011565 47 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Liu KS et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. 2014 Gut pmid:24295850
Miwa S et al. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. 2014 Ann Am Thorac Soc pmid:24298907
Saadat A et al. The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler. 2014 J. Pharm. Pharmacol. pmid:24329164
Rajput P et al. Bifunctional capsular dosage form: novel fanicular cylindrical gastroretentive system of clarithromycin and immediate release granules of ranitidine HCl for simultaneous delivery. 2014 Int J Pharm pmid:24309435
Katayama M et al. Preliminary study of effects of multiple oral dosing of clarithromycin on the pharmacokinetics of cyclosporine in dogs. 2014 J. Vet. Med. Sci. pmid:24189617
Papastergiou V et al. Current and future insights in H. pylori eradication regimens: the need of tailoring therapy. 2014 Curr. Pharm. Des. pmid:24180408
Tan X and Song Z Human saliva-based quantitative monitoring of clarithromycin by flow injection chemiluminescence analysis: a pharmacokinetic study. 2014 Appl. Biochem. Biotechnol. pmid:24166104
Kakuda TN et al. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. 2014 J. Antimicrob. Chemother. pmid:24155058
Seung KJ et al. Salvage therapy for multidrug-resistant tuberculosis. 2014 Clin. Microbiol. Infect. pmid:23991934
Kathariya R et al. Evaluation of subgingivally delivered 0.5% clarithromycin as an adjunct to nonsurgical mechanotherapy in the management of chronic periodontitis: a short-term double blinded randomized control trial. 2014 J Investig Clin Dent pmid:23097216
Furuta T et al. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. 2014 J Clin Pharmacol pmid:24122836
Ratzinger F et al. Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity. 2014 Sci Rep pmid:25500904
Shahbazi Niaz M et al. Investigation into physical-chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles. 2014 Pharm Dev Technol pmid:24093825
Maev IV et al. [Eradication therapy for Helicobacter pylori infection: review of world trends]. 2014 Ter. Arkh. pmid:24779078
Katagiri S et al. [Case report; Disseminated Mycobacterium abscessus infection with hemophagocytic syndrome during treatment of chronic lymphocytic leukemia]. 2014 Nippon Naika Gakkai Zasshi pmid:24796145
Kato M [Expanded indication of National Health Insurance for H. pylori associated gastritis]. 2014 Nippon Rinsho pmid:24912302
Bjerre M et al. Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial. 2014 Scand. J. Clin. Lab. Invest. pmid:25026506
Trotti LM et al. Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: Clinical experience. 2014 J. Psychopharmacol. (Oxford) pmid:24306133
Nie W et al. [The analysis of species identification and susceptibility testing of Mycobacterium abscessus]. 2014 Zhonghua Jie He He Hu Xi Za Zhi pmid:25262693
Campanale M et al. Nickel free-diet enhances the Helicobacter pylori eradication rate: a pilot study. 2014 Dig. Dis. Sci. pmid:24595654
Svanström H et al. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. 2014 BMJ pmid:25139799
Giamarellos-Bourboulis EJ et al. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. 2014 J. Antimicrob. Chemother. pmid:24292991
Zhao Y and Hu ZY Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. 2014 Br. J. Pharmacol. pmid:24283665
Loreto ES et al. New insights into the in vitro susceptibility of Pythium insidiosum. 2014 Antimicrob. Agents Chemother. pmid:25223997
Harvey E and Varatharaj A Round pneumonia. 2014 QJM pmid:23708793
Tsovolou EC et al. Effect of clarithromycin in experimental empyema by multidrug-resistant Pseudomonas aeruginosa. 2014 APMIS pmid:23656439
Altman E et al. Lipopolysaccharide glycotyping of clarithromycin-resistant and clarithromycin-susceptible Canadian isolates of Helicobacter pylori. 2014 Can. J. Microbiol. pmid:24392924
Kim SY et al. Changes in serum immunomolecules during antibiotic therapy for Mycobacterium avium complex lung disease. 2014 Clin. Exp. Immunol. pmid:24354934
De Francesco V et al. Change of point mutations in Helicobacter pylori rRNA associated with clarithromycin resistance in Italy. 2014 J. Med. Microbiol. pmid:24344205
Yamada K et al. Azithromycin inhibits MUC5AC induction via multidrug-resistant Acinetobacter baumannii in human airway epithelial cells. 2014 Pulm Pharmacol Ther pmid:24910464
Jung YS et al. [Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years]. 2014 Korean J Gastroenterol pmid:24561694
Oğuz M and Mihçiokur H Environmental risk assessment of selected pharmaceuticals in Turkey. 2014 Environ. Toxicol. Pharmacol. pmid:24929476
Tranos P et al. Bilateral diffuse iris atrophy after the use of oral clarithromycin. 2014 Cutan Ocul Toxicol pmid:23763291
de Masson A et al. Cavitary pulmonary disease in a patient treated with natalizumab. 2014 Presse Med pmid:24742610
Furuta T et al. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. 2014 J. Gastroenterol. Hepatol. pmid:24224808
Page SR and Yee KC Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. 2014 Intern Med J pmid:25041770
Noguchi S et al. Polymorphic transformation of antibiotic clarithromycin under acidic condition. 2014 J Pharm Sci pmid:24375227
Methaneethorn J et al. A pharmacokinetic drug-drug interaction model of simvastatin and clarithromycin in humans. 2014 Conf Proc IEEE Eng Med Biol Soc pmid:25571290
Phillips RO et al. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. 2014 Antimicrob. Agents Chemother. pmid:24323473
El-Garem Y et al. Seminal Helicobacter pylori treatment improves sperm motility in infertile asthenozoospermic men. 2014 Urology pmid:25432826
Kim SY et al. [Ten day concomitant therapy is superior to ten day sequential therapy for Helicobacter pylori eradication]. 2014 Korean J Gastroenterol pmid:25420735
Mustafa G and Necati B Clarithromycin-associated rhabdomyolysis in an infant. 2014 J Clin Rheumatol pmid:25417692
Hashim H et al. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease. 2014 PLoS ONE pmid:25411976
Yangco BG et al. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? 2014 AIDS Patient Care STDS pmid:24833016
Komiya K et al. Long-term, low-dose erythromycin monotherapy for Mycobacterium avium complex lung disease: a propensity score analysis. 2014 Int. J. Antimicrob. Agents pmid:24948577
Gui J et al. [Subspecies identification for Mycobacterium abscessus group]. 2014 Zhonghua Jie He He Hu Xi Za Zhi pmid:25262692
Ghrew MH et al. Successful renal transplant in patient with controlled pulmonary non-tuberculous mycobacterium infection. 2014 Libyan J Med pmid:25249307
Yoon KH et al. Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea. 2014 J. Korean Med. Sci. pmid:25246742
Higgins JW et al. Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1. 2014 Drug Metab. Dispos. pmid:25106415
Matongo F and Nwodo UU In vitro assessment of Helicobacter pylori ureases inhibition by honey fractions. 2014 Arch. Med. Res. pmid:25240315
Martos M et al. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. 2014 Eur J Gastroenterol Hepatol pmid:25229983
Veraldi S et al. Treatment of sporotrichoid fish tank granuloma with pulsed clarithromycin. 2014 Dermatology (Basel) pmid:25228273
Phillips RO et al. Reply to "compliance with antimicrobial therapy for buruli ulcer". 2014 Antimicrob. Agents Chemother. pmid:25225343
Klis S et al. Compliance with antimicrobial therapy for buruli ulcer. 2014 Antimicrob. Agents Chemother. pmid:25225342
Mitui M et al. Novel Helicobacter pylori sequencing test identifies high rate of clarithromycin resistance. 2014 J. Pediatr. Gastroenterol. Nutr. pmid:25222804
Peng YC et al. Clarithromycin modulates Helicobacter pylori-induced activation of nuclear factor-κB through classical and alternative pathways in gastric epithelial cells. 2014 Clin. Exp. Med. pmid:23129507
Lebedeva MV et al. Clarithromycin as a chiral selector for enantioseparation of basic compounds in nonaqueous capillary electrophoresis. 2014 Electrophoresis pmid:25100556
Katayama M et al. Preliminary study of interaction of clarithromycin with tacrolimus in cats. 2014 J. Vet. Med. Sci. pmid:25099737
Park CS et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. 2014 Am. J. Gastroenterol. pmid:25091062
Cicek-Senturk G et al. Acute mercury poisoning presenting as fever of unknown origin in an adult woman: a case report. 2014 J Med Case Rep pmid:25084829
Bilgin M et al. Acute coronary syndrome secondary to clarithromycin: the first case and review of the literature. 2014 Turk Kardiyol Dern Ars pmid:25080953
Hsu PI et al. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. 2014 Antimicrob. Agents Chemother. pmid:25070099
Patel SK et al. Helicobacter pylori is not eradicated after triple therapy: a nested PCR based study. 2014 Biomed Res Int pmid:25054141
Elkhatib W and Noreddin A Efficacy of ciprofloxacin-clarithromycin combination against drug-resistant Pseudomonas aeruginosa mature biofilm using in vitro experimental model. 2014 Microb. Drug Resist. pmid:25050970
Ohe M and Bohgaki T Successful treatment with clarithromycin for patients with polymyalgia rheumatica. 2014 Korean J. Intern. Med. pmid:25045305
Martin JH and Coombes I Mortality from common drug interactions systems, knowledge and clinical reasoning to optimise prescribing. 2014 Intern Med J pmid:25041768
Bansal S and Chhibber S Phytochemical-induced reduction of pulmonary inflammation during Klebsiella pneumoniae lung infection in mice. 2014 J Infect Dev Ctries pmid:25022293
Dalbøge CS et al. Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. 2014 J. Cyst. Fibros. pmid:24035278
Bonferoni MC et al. Ionic polymeric micelles based on chitosan and fatty acids and intended for wound healing. Comparison of linoleic and oleic acid. 2014 Eur J Pharm Biopharm pmid:24384070
Liu CP et al. NO-releasing xanthine KMUP-1 bonded by simvastatin attenuates bleomycin-induced lung inflammation and delayed fibrosis. 2014 Pulm Pharmacol Ther pmid:23518214
Philips RC et al. Mycobacterium fortuitum infection arising in a new tattoo. 2014 Dermatol. Online J. pmid:24945647
Klesiewicz K et al. PCR-RFLP detection of point mutations A2143G and A2142G in 23S rRNA gene conferring resistance to clarithromycin in Helicobacter pylori strains. 2014 Acta Biochim. Pol. pmid:24927236
Sugimoto M and Furuta T Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. 2014 World J. Gastroenterol. pmid:24914361
Heo J and Jeon SW Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. 2014 World J. Gastroenterol. pmid:24914324
Glatz M and Muellegger RR Drug-associated aquagenic wrinkling of the palms in an atopic male patient. 2014 BMJ Case Rep pmid:24903725
DiCicco M et al. In vitro synergism of fosfomycin and clarithromycin antimicrobials against methicillin-resistant Staphylococcus pseudintermedius. 2014 BMC Microbiol. pmid:24886369
Noonan KA et al. Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. 2014 Cancer Immunol Res pmid:24878583
Gong EJ et al. Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change? 2014 J. Korean Med. Sci. pmid:24851029
Jeon HK and Kim GH Does standard triple therapy still have a role in first-line Helicobacter pylori eradication in Korea? 2014 J. Korean Med. Sci. pmid:24851014
Rasheed F et al. Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance. 2014 Helicobacter pmid:24827414
Jarand J and Field SK Embrace simplicity when treating lady windermere. 2014 Chest pmid:25091749
Luo Q et al. [Clinical effect of clarithromycin therapy in patients with chronic rhinosinusitis]. 2014 Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi pmid:24742507
Trotti LM et al. Further experience using clarithromycin in patients with Kleine-Levin syndrome. 2014 J Clin Sleep Med pmid:24733995
Khalili N Sunny hypomania associated with clarithromycin: a case report. 2014 J Clin Psychopharmacol pmid:24717249
Onyekwere CA et al. Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study. 2014 World J. Gastroenterol. pmid:24707145
Wu JY et al. Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests. 2014 World J. Gastroenterol. pmid:24695835
Sugimoto M et al. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion. 2014 Helicobacter pmid:24690010
Liu KY et al. Efficacy and pharmacological mechanism of pronase-enhanced low-dose antibiotics for Helicobacter pylori eradication. 2014 Antimicrob. Agents Chemother. pmid:24687504
Ikawa K et al. Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages. 2014 J Clin Pharm Ther pmid:24661290
Varvyanskaya A and Lopatin A Efficacy of long-term low-dose macrolide therapy in preventing early recurrence of nasal polyps after endoscopic sinus surgery. 2014 Int Forum Allergy Rhinol pmid:24659566
Lee SH et al. Detection and assessment of clarithromycin inducible resistant strains among Korean Mycobacterium abscessus clinical strains: PCR methods. 2014 J. Clin. Lab. Anal. pmid:24652818
Binh TT et al. Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. 2014 J. Antimicrob. Chemother. pmid:24648504
Karaolia P et al. Reduction of clarithromycin and sulfamethoxazole-resistant Enterococcus by pilot-scale solar-driven Fenton oxidation. 2014 Sci. Total Environ. pmid:24012892
Tursi A et al. Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: a 10-year follow-up study. 2014 Panminerva Med pmid:24637473
Wei Z et al. Rome III criteria cannot distinguish patients with chronic gastritis from those functional dyspepsia patients. 2014 Helicobacter pmid:24617669
Rizzo A et al. Antimicrobial effect of natural polyphenols with or without antibiotics on Chlamydia pneumoniae infection in vitro. 2014 Microb. Drug Resist. pmid:23952319
Wu JY et al. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. 2014 Helicobacter pmid:24612093
Settin A et al. Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism. 2014 Indian J Gastroenterol pmid:24610583
Garza-González E et al. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. 2014 World J. Gastroenterol. pmid:24587620
Zhang J et al. Ocular penetration and pharmacokinetics of topical clarithromycin eye drops to rabbits. 2014 J Ocul Pharmacol Ther pmid:24199739